OverviewSuggest Edit

Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer.

Our cancer diagnostic tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma. These tests potentially address millions of individuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros for diagnostics companies worldwide. Our lead test development program is in colorectal cancer. Further test are in development for lung and prostate cancer. Each of our products in development addresses either mass markets or high-value niches. While some of them lend themselves to partnering with established diagnostics industry players, others can be commercialized effectively by ourselves.

The concept of our diagnostic tests in development relies on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients for disease classification. We believe that we are an industry leader in DNA methylation technologies and biomarkers.

Industry partners as well as the medical and life science communities can access our intellectual property portfolio of over 60 granted any many more filed patents covering DNA methylation technologies and biomarkers as well as our DNA methylation expertise through research products, biomarker services, IVD development collaborations, and licensing.

0
TypePublic
Founded1998
HQBerlin, DE
Websiteepigenomics.com

Latest Updates

Employees (est.) (Feb 2019)43(+3%)
Share Price (Jun 2020)€1.4
Cybersecurity ratingBMore

Key People/Management at Epigenomics

Gregory Hamilton

Gregory Hamilton

Chief Executive Officer
Jorge Garces

Jorge Garces

President & Chief Scientific Officer
Albert Weber

Albert Weber

Executive Vice President Finance
Show more

Epigenomics Office Locations

Epigenomics has offices in Berlin and San Diego
Berlin, DE (HQ)
Geneststraße 5
San Diego, US
11055 Flintkote Ave Suite A
Show all (2)

Epigenomics Financials and Metrics

Epigenomics Revenue

Market capitalization (29-Jun-2020)

66.2m

Closing stock price (29-Jun-2020)

1.4
Epigenomics's current market capitalization is €66.2 m.
Show all financial metrics

Epigenomics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Epigenomics Online and Social Media Presence

Embed Graph

Epigenomics News and Updates

Epigenomics AG Receives MedTech Outlook's 2019 Top 10 In-Vitro Diagnostics Award

- Company recognized for its leadership in advancing blood-based tests to diagnose cancer -

Global Colorectal Cancer Screening Tests Market Key Players, Industry & Opportunity Forecast 2018-2025 Key Players Profile like R-Biopharm, Epigenomics AG, Sysmex Corporation, Quest Diagnostics, Merck Millipore, Kyowa Medex, Companion Dx, Abbott Molecular

Colorectal Cancer Screening Tests Market statistical examining report about the new Advances and Prospects in Colorectal Cancer Screening Tests Market, which serves current and Colorectal Cancer Screening Tests future specialized and financial points of interest of the Colorectal Cancer Screening Te…

Global Sample Preparation in Genomics, Proteomics, and Epigenomics Market 2018 Share, Trend, Segmentation And Forecast To 2023

Sample Preparation in Genomics, Proteomics, and Epigenomics -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

Colorectal Cancer Diagnostic Market with Focus on DNA-Based Tests: Industry Analysis & Outlook (2018-2025)

LONDON, July 24, 2018 /PRNewswire/ -- Colorectal cancer, also known as bowel cancer and colon cancer, is the development of the cancer in the colon or rectum. Download the full report: https://www.reportbuyer.com/product/5479632 A cancer is the abnormal growth of the cells that have the...

Epigenomics Blogs

Epigenomics AG decides to increase share capital by way of private placement

Epigenomics AG / Key word(s): Capital Increase/Corporate ActionEpigenomics AG decides to increase share capital by way of private placement 30-March-2020 / 19:53 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of …

Epigenomics Announces Postponement of Annual General Meeting due to Coronavirus and Preliminary 2019 Flash Financial Results

DGAP-News: Epigenomics AG / Key word(s): AGM/EGM/Preliminary Results17.03.2020 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics Announces Postponement of Annual General Meeting due to Coronavirus and Preliminary 2019 Flash Financial Results Berlin (Germany),…

Centers for Medicare & Medicaid Services open NCD review process for Epi Pro Colon

DGAP-News: Epigenomics AG / Key word(s): Miscellaneous02.03.2020 / 08:00 The issuer is solely responsible for the content of this announcement. Centers for Medicare & Medicaid Services open NCD review process for Epi Pro Colon Opening of review process guarantees reimbursement decision within ne…

Centers for Medicare & Medicaid Services open NCD review process for Epi proColon

Epigenomics AG / Key word(s): MiscellaneousCenters for Medicare & Medicaid Services open NCD review process for Epi proColon 28-Feb-2020 / 23:02 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.…

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG21.01.2020 / 08:56 Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. Notification of Major Holdings 1. Details of issuer Name: Epigenomics AG Street: Geneststraße 5 Postal…

New Micro-Simulation Study in Cancer Medicine Finds Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer

PDF – Adherence rates and screening intervals recognized as decisive elements of successful screening strategies Berlin (Germany), 29 November, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), today reported on micro-simulation model results indicating that Epi proColon®, a colorectal …
Show more

Epigenomics Frequently Asked Questions

  • When was Epigenomics founded?

    Epigenomics was founded in 1998.

  • Who are Epigenomics key executives?

    Epigenomics's key executives are Gregory Hamilton, Jorge Garces and Albert Weber.

  • How many employees does Epigenomics have?

    Epigenomics has 43 employees.

  • Who are Epigenomics competitors?

    Competitors of Epigenomics include Diffinity Genomics, CytoVale and Cernostics.

  • Where is Epigenomics headquarters?

    Epigenomics headquarters is located at Geneststraße 5, Berlin.

  • Where are Epigenomics offices?

    Epigenomics has offices in Berlin and San Diego.

  • How many offices does Epigenomics have?

    Epigenomics has 2 offices.